“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like Vividion Therapeutics Snags $101M from Celgene March 4, 2018 5 Biotechs Quietly Hitting Unusual Volumes Right Now June 22, 2017 MacroGenics Announces Date Of Fourth Quarter And Full Year 2016 Financial Results Conference Call February 16, 2017
MacroGenics Announces Date Of Fourth Quarter And Full Year 2016 Financial Results Conference Call February 16, 2017
